Johnson & Johnson does not expect its top-selling drug, the blockbuster Stelara (ustekinumab) for psoriasis and other inflammatory conditions, to lose US market exclusivity until 2025, strengthening the company’s ability to reach a pharmaceutical revenue target it set several years ago.
J&J Predicts No Stelara Biosimilar Until 2025
After reaching patent settlements with biosimilar drug makers, the company expects to retain exclusivity of its top-selling drug longer than initially expected.
More from Earnings
• By
On its Q1 earnings call, Moderna avoided criticizing policy changes affecting vaccines but de-emphasized its flu/COVID-19 vaccine for under-50 and prioritized cancer programs.
• By
Lilly executives told the company’s Q1 call they were not surprised at the Wegovy deal, but some analysts said it could cut into prescription growth for Zepbound.
• By
CEO Vas Narasimhan urged European governments to spend more to support drug innovation during Novartis's first-quarter results call.
• By
BridgeBio reported $36.7m in Q1 2025 sales of its ATTR-CM drug Attruby, tripling consensus forecasts. Vyndaquel-maker Pfizer acknowledged the product’s impact during the quarter.
More from Business
• By
CEO Vas Narasimhan urged European governments to spend more to support drug innovation during Novartis's first-quarter results call.
• By
Two potentially first-in-class molecules signify Zai Lab’s renewed drive for the in-house discovery of drugs that it requires “to be innovative, differentiated and to have the potential to make a big difference for patients,” its global R&D head tells Scrip.
• By
BridgeBio reported $36.7m in Q1 2025 sales of its ATTR-CM drug Attruby, tripling consensus forecasts. Vyndaquel-maker Pfizer acknowledged the product’s impact during the quarter.